Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.

Abstract

OBJECTIVE:

The purpose of this study was to compare clinical characteristics and survival between patients with stage I epithelial ovarian cancer and fallopian tube cancer.

STUDY DESIGN:

We identified women with stage I epithelial ovarian cancer and fallopian tube cancer who underwent treatment from 2000-2010. Correlation between categoric variables was assessed with χ2 test. The Kaplan-Meier survival analysis was used to generate overall survival data. Factors predictive of outcome were compared with the use of the log-rank test and Cox proportional hazards model.

RESULTS:

The study group consisted of 385 women with epithelial ovarian cancer and 43 women with fallopian tube cancer. Patients with fallopian tube cancer had a higher rate of stage IA disease (65% vs 48%; P=.02) and grade 3 tumors (60.4% vs 30.9%; P<.001). Patients with fallopian tube cancer had a significantly higher rate of breast cancer (25.6% vs 5.7%; P<.001) and BRCA 1 mutations (45.8% vs 9.1%; P<.001). There was no difference in the rates of platinum-based and paclitaxel chemotherapy between the groups. Women with fallopian tube cancer were more likely to have received ≥6 cycles of chemotherapy (58.1% vs 44.1%; P=.02). The 5-year disease-free survival rates were 100% in women with fallopian tube cancer and 93% in patients with epithelial ovarian cancer (P=.04). The 5-year overall survival rates were 100% and 95% for fallopian tube cancer and epithelial ovarian cancer, respectively (P=.7).

CONCLUSION:

We found a higher rate of stage IA, grade 3, and serous carcinoma in fallopian tube cancer. Women with fallopian tube cancer had a higher rate of breast cancer. There was no difference in overall survival between the groups.

• Authors: Jose Alejandro Rauh-Hain, Olivia Wysong Foley, Dina Winograd, Carolina Andrade, Rachel Marie Clark, Roberto Javier Vargas, Emily Moss Hinchcliff, Katherine McKinley Esselen, Neil Stuart Horowitz, Marcela Guadalupe del Carmen
• Journal: American journal of obstetrics and gynecology (Am J Obstet Gynecol) Vol. 212 Issue 5 Pg. 600.e1-8 (May 2015) ISSN: 1097-6868 [Electronic] United States
• PMID: 25514761 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Platinum Compounds
• Paclitaxel

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (epidemiology)
• Carcinoma, Endometrioid (genetics, pathology, therapy)
• Carcinoma, Ovarian Epithelial
• Chemotherapy, Adjuvant (statistics & numerical data)
• Disease-Free Survival
• Fallopian Tube Neoplasms (epidemiology, pathology, therapy)
• Female
• Genes, BRCA1
• Humans
• Kaplan-Meier Estimate
• Middle Aged
• Neoplasm Staging
• Neoplasms, Cystic, Mucinous, and Serous (genetics, pathology, therapy)
• Neoplasms, Glandular and Epithelial (epidemiology, pathology, therapy)
• Ovarian Neoplasms (epidemiology, pathology, therapy)
• Paclitaxel (administration & dosage)
• Platinum Compounds (administration & dosage)
• Prognosis
• Proportional Hazards Models